Arcus Biosciences (RCUS) Q1 2025 earnings summary

Executive summary

• Focus remains on execution and advancing a broad late-stage oncology portfolio, with casdatifan, domvanalimab, and quemliclustat as top priorities targeting substantial unmet needs in renal, lung, gastric, and pancreatic cancers.

• Strategic collaborations with Gilead, AstraZeneca, and Taiho enable cost-efficient development, expanded market access, and co-promotion rights, enhancing financial efficiency and global reach.

• Arcus operates as a single segment, co-developing several programs with Gilead and retaining global rights to its HIF-2a program after Gilead's option expired.

• Raised $150 million in February 2025 through an underwritten offering, with Gilead increasing its stake to 29.7%.

• Multiple pivotal trials are advancing, with upcoming data readouts and study initiations across the oncology pipeline.

Financial highlights

• Q1 2025 revenues were $28 million, down from $145 million in Q1 2024, mainly due to a prior year cumulative catch-up from the Gilead collaboration amendment.

• Net loss for Q1 2025 was $112 million, compared to $4 million in Q1 2024.

• R&D expenses rose to $122 million in Q1 2025, up from $111 million in Q4 2024 and $109 million year-over-year, driven by higher early-stage and preclinical costs.

• General and administrative expenses were $28 million in Q1 2025, down from $32 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $1.0 billion as of March 31, 2025, up from $992 million at year-end 2024, bolstered by the February 2025 offering.

Outlook and guidance

• Cash runway is expected to fund operations through pivotal readouts for casdatifan, domvanalimab, and quemliclustat.

• Full-year 2025 GAAP revenue guidance is $75–90 million.

• R&D expenses projected to peak in 2025 and decline in subsequent years as late-stage programs advance.

• Multiple clinical data readouts and study initiations are planned for 2025 and 2026, including Phase 3 trials in kidney and gastrointestinal cancers.

• No revenue from product sales is expected in the near term; all revenue is from collaborations and licensing.